Recce Pharmaceuticals (ASX: $RCE) secures WHO recognition for RECCE® 327

Recce Pharmaceuticals Ltd (ASX: $RCE) has achieved global recognition by the World Health Organization (WHO) as its primary anti-infective candidate, RECCE® 327 (R327), has been added to the WHO's report of Antibacterial Agents in Clinical Development and Preclinical Development. The unique classification of R327 as an adenosine triphosphate (ATP) production disruptor underscores its significance in combating antimicrobial resistance.

Executive Commentary

We are pleased that R327 has been included in the list of antibacterial products aimed at tackling the urgent global health threat posed by antibiotic resistance. There is a demand for new antibiotic therapies, and this report further showcases R327's potential as a novel treatment for a broad range of life-threatening and resistant bacteria.

Summary

Recce Pharmaceuticals Ltd (ASX: $RCE) has achieved a significant milestone with the inclusion of RECCE® 327 (R327) in the World Health Organization's (WHO) report of Antibacterial Agents in Clinical Development and Preclinical Development. The unique classification of R327 as an adenosine triphosphate (ATP) production disruptor highlights its potential to combat antimicrobial resistance. The company's Chief Executive Officer, James Graham, expressed satisfaction with the recognition, emphasizing the growing demand for new antibiotic therapies. This recognition further underscores R327's potential as a novel treatment for a broad range of life-threatening and resistant bacteria. The company's anti-infective pipeline, including R327, R435, and R529, aims to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens, leveraging its unique technologies to meet unmet medical needs.